St. Petersburg Times
World & Nation
Special report
Video report
  • For their own good
    Fifty years ago, they were screwed-up kids sent to the Florida School for Boys to be straightened out. But now they are screwed-up men, scarred by the whippings they endured. Read the story and see a video and portrait gallery.
  • More video reports
Multimedia report
Print Email this storyEmail story Comment Letter to the editor
Fill out this form to email this article to a friend
Your name Your email
Friend's name Friend's email
Your message

FDA targets unapproved cough and cold drugs

Published May 26, 2007


WASHINGTON - Manufacturers of unapproved extended-release cough and cold drugs that contain the expectorant guaifenesin have until Nov. 25 to stop shipping the medicines, health officials said Friday.

The Food and Drug Administration said about 20 companies make hundreds of timed-release medicines containing guaifenesin that have never undergone agency review. They are expected to stop making the drugs by Aug. 27. The drugs are sold both by prescription and over the counter, and as both single-ingredient and combination products.

The action does not affect products containing guaifenesin in immediate-release form, the FDA said. The agency said it knew of no safety issues with guaifenesin.

Only Adams Respiratory Therapeutics Inc. has FDA approval to sell extended-release guaifenesin. In 2002, the FDA approved single-ingredient versions of the medicines, sold as Mucinex and Humibid. Friday's move by the FDA immediately benefited the Chester, N.J. company: Its shares were up 9.86 percent, to $44, in early afternoon trading.

The FDA identified Crantex and Guaifenex as among the biggest selling names of unapproved guaifenesin medicines, as of 2006. Crantex's distributor, Breckenridge Pharmaceutical Inc. of Boca Raton, will halt distribution by the deadline, said Larry Lapila, vice president of business development. A message left with Ethex Corp., the St. Louis company that distributes Guaifenex, was not immediately returned.

Any company that wants to sell medicine containing guaifenesin in timed-release form must seek FDA approval, the agency said. Approval would be subject to patent rights held by Adams Respiratory Therapeutics.

Fast Facts:


Guaifenesin has been used in medicine for decades. It thins the mucus in the air passages and makes it easier to cough and clear the airways. It relieves the coughs of colds, bronchitis, and other lung infections. Side effects can include headache, upset stomach and vomiting.


[Last modified May 26, 2007, 02:31:02]

Share your thoughts on this story

[an error occurred while processing this directive]
Subscribe to the Times
Click here for daily delivery
of the St. Petersburg Times.

Email Newsletters